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Abstract 
Background and Aims 
As people age there is a progressive dysregulation of the immune system that may 
lead to an increased risk of infections, which may precipitate hospital admission in 
people with chronic heart or respiratory diseases. Mineral and vitamin 
supplementation in older people could therefore influence infections in older people.  
However, the evidence from the available randomised controlled trials is mixed. The 
aim of the study was to assess the relative efficiency of multivitamin and 
multimineral supplementation compared with no supplementation.   
 
Methods 
Cost-utility analysis alongside a randomised controlled trial. Participants aged 65 
years or over from six general practices in Grampian, Scotland were studied. They 
were randomised to one tablet daily of either a multivitamin and multimineral 
supplement or matching placebo.  Exclusion criteria were:  use of mineral, vitamin or 
fish oil supplements in the previous three months (one month for water soluble 
vitamins), vitamin B12 injection in the last three months.   
 
Results 
Nine hundred and ten participants were recruited (454 placebo and 456 
supplementation).   Use of health service resources and costs were similar between 
the two groups.  The supplementation arm was more costly although this was not 
statistically significant (£15 per person, 95% CI -3.75 to 34.95).  After adjusting for 
minimisation and baseline EQ-5D scores supplementation was associated with fewer 
QALYs per person (–0.018, 95% CI -0.04 to 0.002).  It was highly unlikely that 
supplementation would be considered cost-effective. 
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Conclusions 
The evidence from this study suggests that it is highly unlikely that supplementation 
could be considered cost-effective. 
 
Keywords 
Cost effectiveness; Nutrition; Quality of life; Randomised controlled trial; Oral 
nutritional supplementation; Vitamins and Minerals. 
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Introduction 
 
As people age there is a progressive dysregulation of the immune system.1 This 
decline in immunity may lead to an increased risk of infections, which may 
precipitate hospital admission in people with chronic heart or respiratory diseases.2 
A further consequence may be the depletion of nutritional reserves, which may also 
be sub-optimal for the prevention of future infections.3 Mineral and vitamin 
supplementation in older people could therefore influence infections in older people. 
However, the evidence from the available randomised controlled trials (RCTs) is 
mixed.4-8 These trials were generally of small size and none included an economic 
evaluation.   
 
We undertook a large randomised placebo controlled trial of multivitamin and 
multimineral supplementation in doses commonly provided in over-the-counter 
preparations amongst people aged 65 years and older, examining the effects on 
morbidity from infections.9 Part of this study involved the prospective collection of 
participant-specific resource use and health-related benefits for the twelve-month 
period following randomisation. This paper reports a cost-utility analysis 
undertaken from the perspective of the UK National Health Service (NHS) of 
supplementation versus no supplementation.   
 
Methods 
Design 
Details of the design of the RCT are available elsewhere.9 In brief this was a 
pragmatic randomised double-blind, placebo-controlled trial.  Nine hundred and ten 
participants were recruited from six general practices in Grampian, Scotland, 
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between February and December 2002 and randomised to either placebo (n = 454) or 
a multivitamin and multimineral supplement (n = 456) and were followed up for 12 
months. Of these 32 withdrew from the study (18 placebo and 14 supplement).  
Furthermore, 77 stopped taking the tablets but did not withdraw from the trial (39 
placebo, 38 supplement).   
 
A detailed description of the clinical outcomes are reported elsewhere.9 All people 
aged 65 years and over were eligible unless their general practitioners (GPs) 
considered them too unwell to participate. Participants were excluded if they had 
used oral mineral, vitamin or fish oil supplements in the previous three months (one 
month in the case of water soluble vitamins only), or vitamin B12 injection in the last 
three months. Written informed consent was collected from participants and the 
Grampian Research Ethics Committee gave approval for the study. Participants were 
randomised to one tablet daily of either a commercially available multivitamin and 
multimineral supplement (800mcg vitamin A, 60mg vitamin C, 5mcg vitamin D, 
10mg vitamin E, 1.4mg thiamin, 1.6mg riboflavin, 18mg niacin, 6mg pantothenic 
acid, 2mg pyridoxine, 1mcg vitamin B12, 200mcg folic acid, 14mg iron, 150mcg 
iodine, 0.75mg copper, 15mg zinc, 1mg manganese) or matching placebo.   
 
Measurement of costs 
Estimation of NHS resource use 
In over 94% of cases the use of health services resources in primary care was 
collected principally from a review of primary care notes by a member of the trial 
team (AM or AS) using a data abstraction form linked to a Microsoft Access 
databaseTM. These data were supplemented with participant information elicited 
from a patient diary when detailed information was provided (e.g. the participant 
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gave exact details of an antibiotic prescription received from their GP not detailed in 
the primary care notes), and for the few cases where the health authority had 
removed the primary care notes of the participants who had died. The data collected 
from primary care records related to the number and type of antibiotic prescriptions 
in primary care (and total number of days that antibiotics were prescribed); number 
of primary care contacts; number of hospital admissions (in total and those related to 
infection); number of days in hospital with infection; total number and number of 
infection-related outpatient visits; adverse events reported by participants; 
compliance with trial medication (from monthly diary report in all participants and 
tablet count at six and twelve months in a random sample of 10% of participants).  
Hospital data were obtained from computerised patient administration systems, 
hospital and primary care notes.   
 
All analyses of outcomes including the economic evaluation were conducted on an 
intention to treat basis. Table 1 describes the main elements of resource use in the 
trial. 
 
Derivation of costs 
Average unit costs of each aspect of resource use were obtained from reliable and 
widely used published sources for inpatient and day case admissions, outpatient and 
primary care contacts and antibiotic use.10-13 The cost of the multivitamin and 
multimineral supplement was based on the purchase cost.  Costs were derived using 
unit costs for 2003 UK £ sterling. Data describing the resource utilisation of 
participants were combined with estimates of unit costs for each of the areas of 
management considered. This allowed estimation of total cost for each participant, as 
well as the average cost for each area of resource utilisation and average total cost. 
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As unit costs differ between, for example type and place of contact, the estimates of 
resource utilisation used for the estimation of cost were more disaggregated than 
those used in the analysis described above. The main unit costs used in the analysis 
are reported in Table 1. 
 
Missing cost data were rare (about 0.5%) and assumed to be missing completely at 
random. The incremental (difference) in mean cost between groups was based on an 
analysis of covariance adjusting for the factors used in minimisation (i.e. treatment, 
gender, age 74-84y, age 85y and above, and residence type).   
 
Derivation of Quality Adjusted Life Years (QALYs) 
The health outcomes of the economic evaluation were expressed in terms of quality 
adjusted life years (QALYs); other clinical endpoints are reported in the main trial 
report.9  QALYs have been used in order to reflect the effect of supplementation on 
an individual’s health related quality of life. QALYs were estimated from the 
participant’s responses to the EuroQol (EQ-5D) questionnaire collected at baseline, 
six and 12 months. The EQ-5D is a generic measure of health status that defines 
health in terms of five dimensions: mobility, self-care, usual activities, pain or 
discomfort, and anxiety or depression. Each of these dimensions has three levels: no, 
moderate or extreme problems. The combinations of these dimensions and levels 
provide 243 possible health states. The responses of participants were converted into 
utilities using a tariff scale derived from a sample of UK general public.14 The 
approach used to generate QALYs has been extensively validated and has recently 
been recommended for decision making by the National Institute for Health and 
Clinical Excellence (NICE) UK.15 
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As the number of missing QALY responses was less than 10%, missing data were 
assumed to be missing completely at random (that is non-responders do not differ 
systematically from responders). An alternative approach was also adopted that 
imputed the missing data using the mean responses of those that did provide a 
response. The incremental QALYs between groups were based on analysis of 
covariance, adjusting for the factors used in minimisation (i.e. treatment, gender, age 
74-84, age 85 and above, and residence type), and EQ-5D baseline scores.   
 
Assessment of cost-effectiveness 
Data reported as mean costs for both cases and controls were derived for each item 
of resource use and then compared using unpaired t-tests. Using the estimates of 
incremental cost and QALYs, the incremental cost per QALY ratio (ICER) was 
estimated to assess the likelihood of the intervention being more cost effective. 
Decisions about the acceptability of a technology as an effective use of NHS 
resources are based primarily on the cost-effectiveness estimate of below an ICER of 
£20,000 per QALY.15 As the data were not normally distributed non-parametric 
bootstrapping was used to estimate credible limits around the difference in cost for 
each area of resource use, mean total cost, and mean QALYs.16 No discounting of 
costs and effects was performed, as the time horizon was only one year.   
 
Sensitivity analysis 
Sensitivity analysis is necessary to assess the robustness of the qualitative conclusion 
and identify where areas where research needed to more precisely estimate the 
values of those variables to which the result is sensitive.17 The variables that were 
considered uncertain in this study related to the cost of the different services used.  
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Therefore one-way sensitivity analysis was conducted using plausible variations in 
the cost of inpatient and outpatient services.   
 
Results 
Description of the participants (Table 2) 
The median age of intervention and placebo groups was 72 and 71 years respectively. 
Four percent of participants were aged 85 years or older, 3% lived in nursing homes. 
More than half took three or more different drugs daily, 30% had heart disorders, 
19% had chest disorders and 29% were at risk of either iron, folate, vitamin C or 
vitamin D deficiency. 
 
The supplemented group had 150 hospital admissions during the trial, of which 22 
were for the treatment of infection. The figures for the placebo group were 125 and 
23, respectively.  The differences between groups were not statistically significant (P 
> 0.05).9  
 
Costs 
The summary of the mean cost per patient of the two interventions is presented in 
Table 3. This table summarises both resource use and costs and shows that the main 
determinant of incremental cost was the cost of the supplements. The mean total cost 
per patient in the multivitamin and multimineral supplement arm was £90 (standard 
deviation (SD) £155, median £38) and of the placebo arm £75 (SD £142, median £21). 
The difference in mean cost was £15 (95% CI -£4 to £35).   
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Quality-adjusted life years 
Table 4 reports the EQ-5D scores for each arm of the trial at baseline, six and 12 
months. Also reported are the differences between arms in EQ-5D score at six and 
twelve months.  From these data it was estimated that the mean QALYs were 0.771 
(SD 0.22, median 0.796) for the multivitamin and multimineral supplement arm and 
0.789 (SD 0.20, median 0.796) for the placebo arm.  The mean difference in QALYs 
after adjusting for minimisation and baseline EQ-5D scores was –0.018 (95% CI –0.04 
to 0.002) i.e. the placebo arm was associated with more QALYs, although the 
difference was not statistically significant. 
 
Estimation of cost-effectiveness 
In terms of mean incremental cost per QALY the placebo intervention was dominant 
(less costly and at least as effective). Furthermore, the results of the bootstrapping 
exercise indicated that it was highly unlikely (1% likelihood) that supplements could 
provide additional benefits at a price considered affordable by society.  
 
Sensitivity analysis 
The total costs were derived in several ways: by imputing the missing costs, 
including all outpatient and in-patient costs. Sensitivity analyses were carried out for 
outpatient service costs included the costs of day cases and accident and emergency 
visits. The inpatient costs were also calculated based upon all hospital admissions 
and imputed speciality costs. These results were not sensitive to any of the changes 
around costs made in the sensitivity analyses performed.  
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Discussion 
The use of a multivitamin and multimineral supplement, similar to many of the 
products available over the counter, is unlikely to be cost-effective in this population 
for the UK. This conclusion was not affected by any of the sensitivity analyses 
performed or the inclusion of a stochastic analysis of costs and QALYs. This latter 
approach has been advocated in situations where no difference in outcomes has been 
detected to quantify the likelihood that a more costly intervention could also be more 
effective.15 In our situation this likelihood was found to be very low (estimated at 
1%). Interventions with a cost per QALY of £20,000 are generally recommended for 
use in the UK NHS. Multivitamin and multimineral supplementation is highly 
unlikely to meet this criterion.   
 
The trial population is representative of the elderly population living in the 
community but included very few people aged 85 years or over or living in nursing 
homes, many of whom may be of higher risk of nutritional deficit.18 However, people 
already taking supplements were also excluded and these people have been shown 
to have healthier diets.17   
 
The method used to elicit QALYs might have failed to capture some beneficial aspect 
of multivitamin and multimineral supplementation. However, there appeared to be 
no evidence of a difference when health was measured using the SF-12 nor in the 
number of infection days per person.9 These results are in concordance with those 
from similar trials6,8 although some evidence of borderline effectiveness has been 
reported.19,20 There was also a high proportion of people with zero costs in each 
section as resource utilisation was quite low. 
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Conclusions 
In conclusion, regular use of commonly available multivitamin and multimineral 
supplements by older people living in the community not already taking 
supplements is unlikely to be cost-effective. It is unclear whether this conclusion also 
holds for older people or those living in nursing home care. 
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 Table 1: Methods of data collection and outcomes 
  
Variables  Average unit 
cost 
Minerals and vitamins  £17.20 
GP consultations Per surgery consultation (9.36 mins)11 
Per telephone consultation (10.8 mins)11 
Per home visit (13.2 mins)11
£20 
£23 
£61 
Nurse Per consultation11 
Per home visit11
£8 
£18 
Dentist General dentist appointment13 £6.65 
Antibiotics prescribed Cost of actual antibiotic (British National 
Formulary)12
Varied 
Contacts with other care providers   
Out patient appointments ISD Scotland National Statistics10 £73 
A and E contact Ref costs (minor injuries within A&E)10 £37 
Day case ISD Scotland10 £334 
Inpatient stay Personal Social Services Research Unit 
(PSSRU) 11
£147 
 
 
10,11,12,13 refer to references. 
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Table 2: Description of participants. Values are numbers (percentages) unless 
stated otherwise 
Characteristics Supplement group  Placebo group  
 n=456 n=454 
Median (interquartile range) age (years) 72 (68.0-76.0) 71 (68.0-76.0) 
Aged ≥85 19 (4) 16 (4) 
Women 217 (48) 214 (47) 
Mean (SD) body mass index (kg/m2) 28.2 (4.2) 27.9 (4.1) 
 n=456 n=453 
Current smoker 57 (13) 63 (14) 
Current No of different drugs taken: n=455 n=453 
 0-2 205 (45) 234 (52) 
 3-6 198 (44) 164 (36) 
 >6 52 (11) 55 (12) 
Past and present chronic conditions: n=456 n=454 
 Hypertension 188 (41) 172 (38) 
 Heart disorders 137 (30) 130 (29) 
 Chest disorders 86 (19) 87 (19) 
 Diabetes 37 (8) 42 (9) 
 Cancer 46 (10) 46 (10) 
 Cerebrovascular disease 31 (7) 22 (5) 
Chronic infection present at recruitment 42 (9) 38 (8) 
Injection in past year to prevent influenza  432 (95) 423 (93) 
Place of residence:   
 Community 440 (97) 439 (97) 
 Nursing home 16 (3) 15 (3) 
Housing tenure:   
 Owner occupier 340 (75) 332 (73) 
 Public sector tenant* 88 (19) 92 (20) 
 Other 28 (6) 30 (7) 
Nutrient at high risk of being deficient†:   
 Iron 73 (16) 37 (8) 
 Folate 25 (6) 21 (5) 
 Vitamin C 58 (13) 59 (13) 
 Vitamin D 70 (15) 49 (11) 
 At risk for any of above 145 (32) 117 (26) 
*For example, council house tenant. 
†On basis of micronutrient risk scores, see:  http://www.foodfrequency.org/naq
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Table 4 EQ-5D scores 
 
 Treatment 
n = 456 
Control 
n = 454 
Adjusted 
difference* 
CI P value 
Baseline  0.75 (0.23) 0.78(0.19)    
6 months 0.77(0.22) 0.80(0.20) -0.014 [-0.034, 0.006] 0.18 
12 months 0.77(0.22) 0.80(0.19) -0.018 [-0.04, 0.002] 0.08 
 
() Standard deviations 
* Difference adjusted for minimisation factors and baseline EQ-5D 
